Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis

FibroGen, Inc. (NASDAQ:FGEN), announced on 5/21/18 that updated results from the company’s randomized, double-blind, placebo-controlled Phase 2b PRAISE study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF) were presented in several poster presentations at the American Thoracic Society (ATS) 2018 in San Diego, California. In total, the company is presenting four abstracts on pamrevlumab.